ARGERIS KARABELAS

Argeris Karabelas is a highly respected Venture Partner at ATP (Apple Tree Partners), a prominent life sciences venture capital firm renowned for its commitment to building transformative healthcare companies. In his pivotal role, Mr. Karabelas leverages an extensive career marked by significant leadership and operational success within the pharmaceutical and biotechnology sectors to identify, evaluate, and cultivate promising new ventures.

ATP (Apple Tree Partners) specializes in creating and investing in innovative life sciences companies, often from inception. Argeris Karabelas's deep industry knowledge and strategic acumen are invaluable to this process. He provides critical guidance to ATP's portfolio companies, helping them navigate complex development pathways, scale operations, and achieve their clinical and commercial objectives. His contributions are instrumental in shaping the strategic direction of these emerging companies, ensuring they are well-positioned for success in a competitive landscape.

Prior to joining ATP, Mr. Karabelas built an impressive career spanning several decades at the forefront of the global pharmaceutical industry. He served as the President of Wyeth Pharmaceuticals, where he oversaw a vast portfolio and played a key role in the company's strategic initiatives. His leadership extended to Novartis, where he held various senior executive positions, including Head of Global Pharma Operations and CEO of Novartis Pharma AG. Furthermore, he was the President and CEO of Vanda Pharmaceuticals, a company he successfully led through significant growth and development phases. These roles provided him with unparalleled experience in drug discovery, clinical development, regulatory affairs, and global commercialization.

Argeris Karabelas's investment focus at ATP naturally aligns with the firm's core mandate: pioneering advancements in life sciences. This includes areas such as novel drug discovery, biotechnology, medical devices, and digital health solutions that address unmet medical needs. His operational background allows him to critically assess the scientific merit, commercial viability, and execution capabilities of potential investments, making him a crucial asset in ATP's investment decision-making process.

While specific individual investments are often a collaborative effort within ATP, Mr. Karabelas's profound experience directly contributes to the firm's track record of backing successful companies that bring innovative therapies to patients. His ability to mentor founders and management teams, coupled with his strategic vision, helps transform scientific breakthroughs into impactful healthcare solutions. Argeris Karabelas embodies the operational expertise that ATP values, reinforcing its mission to build enduring companies that redefine the future of medicine.